The HANDI Resources Center Team is pleased to announce new 2024 scholarship opportunities available for the bleeding disorders community!
Meet NHF's Chapter Development Specialist, Nick Kallinicou! Nick took his passion for meaningful and impactful work and joined NHF. He continues to be a vital part of the NHF community and assisting families and patients.
The U.S. Food and Drug Administration (FDA) has accepted CSL Behring’s Biologics License Application (BLA) for priority review of etranacogene dezaparvovec, an investigational gene therapy for hemophilia B.
This session will present findings from a national needs assessment conducted by NBDF in partnership with the CDC about the experiences and needs of people with bleeding disorders within African American communities. The group will discuss implications for individuals, chapters, and partners to serve African American communities.
